The researchers examined the prevalence of steatosis, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis in individuals with metabolically healthy obesity and metabolically abnormal obesity...
A research team has determined the risk factors for moderate to severe hepatic steatosis among patients with HIV by comparing the prevalence rates of hepatic steatosis among patients with HIV vs without...
Several biomarkers obtained through non-invasive means could help to predict the development of non-alcoholic fatty liver disease in patients living with HIV (PWH), according to recent research.
The FibroScan-AST (FAST) score has been shown to be effective for the risk assessment of non-alcoholic hepatic steatosis (NASH) in patients without HIV, but its effectiveness in HIV+ patients is currently...
Certain biomarkers could be used to identify people living with HIV who are at increased risk of developing non-alcoholic fatty liver disease, according to recent research.
